Abstract Compound 1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one (VAM2-6) was evaluated against a blood-induced infection with chloroquine-sensitive Plasmodium yoelii yoelii lethal strain in CD1 mice in a 4-day test scheme. LD50 of the compound was 56.51 mg/kg and LD10 was 20.58 mg/kg (taken as the highest dose). Animals were treated by oral gavage of 20, 10, and 5 mg/kg. Mice in the untreated control group showed a progressively increasing parasitemia leading to mouse death on 6 days post-infection; in this group, all mice showed parasites in the blood on the fifth day of sampling; the mean parasitemia on that day was 19.4 %. A 4-day dosage of 20 mg/kg of VAM2-6 showed a 97 % chemosuppression of total parasitemia on the fifth day, a 28 days survival time, and 20 % of cured animals. A 4-day dosage of 10 and 5 mg/kg showed 85 and 37 %, respectively, chemosuppression of total parasitemia on the fifth day; but all mice died from days 6 to 9 post-infection with increasing parasitemia. Mice treated with chloroquine at 5 mg/kg survived during the experiment. The results obtained in this study showed that the infection outcome of P. yoelii yoelii-infected mice is affected by VAM2-6 compound by slowing down the parasite replication, retarding the patency time, and increasing their survival time. Although compound VAM2-6 was active at higher doses than chloroquine, these results leaves a door open to the study of its structure in order to improve its antimalarial activity.
Introduction
Of all the parasitic diseases, malaria is the number one killer (Zhang et al. 2012) . It is the underlying cause of death for 1.24 million individuals including 714,000 children younger than 5 years and 524,000 individuals aged 5 years or older (Murray et al. 2012) . This disease has a high rate of resistance outbreaks and a constant need for discovery of novel antimalarials and drug targets. Efforts to develop an effective malaria vaccine are yet to be successful and thus chemotherapy remains the mainstay of malaria control strategy. This dire situation is aggravated by reports from Southeast Asia of the parasite becoming resistant to the "magic bullet" artemisinins, the last line of defense in malaria chemotherapy (Giha 2010; Muregi et al. 2011) .
In this context, part of our research group has recently introduced a novel scheme to perform rational-in silico-molecular design (or selection/identification of lead drug-like drug chemicals) and quantitative structure-activity (QSAR)/property relationship studies, known as TOMOCOMD-CARDD (acronym of TOpological MOlecular COMputer Design-Computer Aided "Rational" Drug Design). This method has been developed to generate 2-D (topological), 2.5 (3-D-chiral), and 3-D (topographical and geometrical) molecular descriptors based on the application of discrete mathematics and linear algebra to chemistry. This in silico method has been successfully applied to the prediction of several physical, physicochemical, chemical, and biological properties of organic compounds (MarreroPonce et al. 2004; Montero et al. 2006; Rivera et al. 2009; Vega et al. 2006) . Nonstochastic and stochastic bond-type bilinear indices were used to generate predictive linear discriminant analysis-assisted QSAR models, enabling the selection of novel drug-like compounds with antitrichomonal activity (new molecular subsystem of 8[VAM2-1 to 8] 4-[5-(dialkylamino)pentyl]quinoxalin-2-ones) (Rivera et al. 2009 ). The biological activity of these compounds was tested in vitro at concentrations of 100, 10, and 1 μg/mL on TvJH31A strain. Compound 1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4-dihydroquinoxalin-2(1H)-one (VAM2-6) exhibited pronounced trichomonacide activity of 100, 92.63, and 86.52 % at 100, 10, and 1 μg/mL, respectively, as well as nonspecific cytotoxicity at 10 μg/mL at 24 h. Recently, this compound was tested by in vitro cell-based assay using a radioisotopic microtest in Plasmodium faciparum strain 3D7 (unpublished data); every compound was evaluated against cultured intraerythrocytic asexual forms of the human malaria parasite P. falciparum. The uptake of [G-3H] hypoxanthine by parasitized erythrocytes in the microtiter plates was used as an indicator of drug activity. VAM2-6 was the most active compound in this evaluation at 100 μg/mL. Based on these results, we decided to evaluate the efficacy of compound VAM2-6 in a malaria murine model infected with Plasmodium yoelii yoelii lethal strain.
Materials and methods
Animals Animals were obtained from the Faculty of Medicine, UNAM vivarium. Male CD1 mice weighing 26 g were used for the experiments. Animals were kept in polyethylene cages with temperature, humidity, and filtered air-regulated environment conditions. Management was performed according to the Mexican Official Norm NOM-062-ZOO-1999 for the production, care, and use of laboratory animals. Mice were divided into groups of five mice each.
Parasites P. yoelii yoelii lethal strain was obtained from the London School of Hygiene and Tropical Medicine and maintained by serial passages in CD1 mice.
Chemicals and dosing
Compound VAM2-6 (1-methyl-7-nitro-4-(5-(piperidin-1-yl)pentyl)-3,4 dihydroquinoxalin-2(1H)-one) (Fig. 1) was kindly provided by Dr. Vicente J. Arán (Rivera et al. 2009 ). VAM2-6 compound was first dissolved in dimethyl sulfoxide (DMSO, 99.5 %; J.T. Baker, México) and then diluted in phosphate-buffered saline (PBS, in millimolar; 138 NaCl, 2.7 KCl, 8.1 Na 2 HPO 4 , 1.1 KH 2 PO 4 , pH 7.2). Drugs were assayed in the range of 20, 10, and 5 mg/kg body weight with a concentration of solvent DMSO of 0.5 % which was harmless to host. Compound was administrated by oral gavage, each mouse receiving the dose four times at intervals of 24 h in a final volume of 100 μL. The concentrations were chosen on the basis of our previous acute toxicity test in mice based on Lorke's method (Lorke 1983) and following the Organisation for Economic Co-operation and Development recommendations for acute treatments in toxicology assays.
Lethal dose 50
Lethal dose 50 (LD50) test was made on six lots of five CD1 male mice each, the experimental mice (five lots) received different oral gavage per lot doses of the compound (100, 60, 40, 10, and 5 mg/kg), and the control mice (one lot) received just the vehicle (DMSO, 0.5 %). LD50 was calculated with Biostat® software (version 5.7.4.0). The LD50 value obtained was used as a reference to calculate LD10 and the different doses of the compound used in the in vivo assay, taking LD10 value as the highest dose.
In vivo antimalarial assay
The evaluation of the compound against P. yoelii yoelii was carried out using the classic 4-day suppression test describes by Peters and Robinson (1992) . Five lots of five mice each were formed. Each mouse received 25× 10 3 parasitized erythrocytes inoculated by intraperitoneal route. Mice from each experimental dose received one of the three calculated doses (20, 10, and 5 mg/kg). Each mouse received the dose four times at intervals of 24 h, dispensing the first dose 4 h after inoculation of the parasite. Positive control group was treated orally with chloroquine (5 mg/kg) and DMSO (negative control group) with 0.5 % DMSO in H 2 O. On the fifth day, a blood smear was made to all mice and the percent individual parasitemia was estimated. The percentage of chemosuppression of total parasitemia for each dose were calculated as [(A-B/A]×100 as described by Argotte et al. (2006) where A is the mean parasitemia in the untreated control group and B is the parasitemia in each experimental group. Animals from the treated and control groups were followed up until the end of the experiment (30 days after being infected), blood samples were taken from all dying animals to estimate parasitemia, and the day of death was registered. We regarded as cured those mice that survive up to the end of the experiment and did not show parasites in the blood smear taken before they were discarded. Mean parasitemia and standard deviation were calculated per lot.
Statistical analysis
Statistical differences between mean parasitemia of the control and experimental mice groups, percent inhibition on the fifth day, as well as range and mean survival time were assessed with SigmaStat® software, 3.5 version, using Student's t test and ANOVA with the Tukey's test (P values of 0.05 or less were considered significant). Table 1 showed the results obtained in our toxicity test; LD50 of the compound was 56.51 mg/kg and its confidence limit was 39.11-76.28, LD10 was 20.58 mg/kg.
Results

LD50 regression statistics
In vivo antimalarial assay All negative control mice showed parasites in the blood on the fifth day of sampling and the mean parasitemia on that day was 19.4 %. All mice in this control group died between 6 and 7 days after infection with a mean parasitemia of 44.8 %; so lethally, in this group, 100 % was estimated to have a mean survival of 6.2 days. Animals from chloroquine control group showed a mean parasitemia of 0.26 % on the fifth day of sampling with 98.66 % chemosuppression of total parasitemia. All mice were completely cured with no parasites in their blood at 30 days after infection.
From the five animals receiving the highest dose (20 mg/kg), only two became infected showing blood parasites on the fifth day with of 1.1 and 1.8 % of parasitemia, respectively, and expiring on days 25 and 28, respectively, with 22.15 % mean parasitemia. Three blood-negative mice became infected after the fifth day, two of them died at day 29 with parasitemia of 16.8 and 17 %, respectively. The last mice of this group survived in healthy conditions up to the end of the experiment and no parasites were demonstrated in its blood at the time it was discarded, so it was considered cured. Lethality on the lot treated with 20 mg/kg was 80 % with 20 % cured. The chemosuppression of total parasitemia on this group was 97.01 % and the survival mean time was 28.2 days; infected mice died with a mean final parasitemia of 13.46 %.
All the animals in the 10 mg/kg-treated group became infected showing a mean parasitemia of 2.8 % at the fifth day of sampling, a mean survival time of 9.8 days, and with a mean final parasitemia of 33.2 %. The chemosuppression of total parasitemia was 85.5 % for this group. In the group treated with 5 mg/kg, all the animals showed parasites in the blood after the fifth day with 12.08 % mean parasitemia, 7 days survival mean time, 37.76 % chemosuppression of total parasitemia. This group presented a mean final parasitemia of 44.2 %.
Chemosuppression of total parasitemia on the fifth day are depicted in Table 2 . Mean survival time, death, and cure of mice are depicted in Table 3 .
Discussion
At the beginning of the current decade, the increasing burden of malaria was attributed to the parasite resistance to affordable antimalarial drugs, chloroquine, sulphadoxine/-pyrimethamine, and recently to artemisisnina (Giha 2010; Jensen and Mehlhorn 2009) . The increasing spread of malaria together with the emergence of resistance against conventional antimalarial drugs has put enormous pressure on the public health systems to introduce new therapeutics. Research efforts on the discovery of new antimalarial drugs have generated only a handful of successful compounds suitable for the treatment and prevention of acute symptoms of malaria (Schlitzer 2008) . In the present study, the efficacy of a novel quinoxalinone (compound VAM2-6), was evaluated against P. yoelii yoelii lethal strain. Our results were analyzed in two different moments, first chemosuppression of total parasitemia on the fifth day in different groups, when application of the compound has just been interrupted 24 h before, exactly when the direct effect exerted by the compound on the parasite multiplication can be measured; and second, survival time after the fifth day when the parasites were freed from the action of the compound. According to the parasitemia mean values observed on the fifth day in the different groups, inhibition of the replication of the parasites decreases in a dose-dependent manner; maximum dose corresponds to the highest percentage of chemosuppression of total parasitemia. There was a relation between the time of patency of infection and the terminal parasitemia observed before death; mice with over 3 % parasitemia on the fifth day died with more than 40 % parasitemia, while those whose parasitemia is lower than 3 % or became infected after the fifth day died with parasitemia below 40 %. Detectable number of parasites in blood was retarded in three mice treated with 20 mg/kg; nevertheless, two of them died after 26.33 days. This temporal arrest on parasite multiplication seems to confer an advantage to the host in terms of survival time in comparison to the control group. The multiplication of the parasite was completely stopped in one animal of the group treated with the highest dose. In the other mice of all the treated groups, multiplication was slowed down in a dosedependent manner, and patency time lasted abnormally expect for the animals treated with 5 mg/kg that died at 6 days after infection, similar than mice in the control group; in this particular group, multiplication of the parasites seems not to be affected by the compound.
The quinoxaline scaffold is prevalent in a variety of pharmacologically active synthetic and natural compounds. Throughout the twentieth century, the immense use of chloroquine, the most famous drug of this group, provided wellfounded hopes for the eradication of malaria (Kaur et al. 2010) . The known antimalarial drugs from the quinoline family include: 4-aminoquinolines; 4-anilinoquinolines; 8-aminoquinolines; quinolines from nature, quinolones, isoquinolines, and tetrahydroquinolines; ring-modified quinolines; and miscellaneous quinolines. These drugs mostly act during the blood stages of the parasite's life cycle but some target the hepatic stages as well (Baird and Rieckmann 2003; Kaur et al.2010) . The quinolines are known to inhibit the polymerization of heme and prevent disposal of polymers from the food vacuole to the cytoplasm where hemozoin is formed (Sharma and Mishra1999) . This leads to intraparasitic accumulation of free heme, which is highly toxic to the parasite. VAM2-6 is a quinoxaline derivative but nothing is known about its mode of action. The results obtained in this study showed that the infection outcome of P. yoelii yoelii-infected mice is affected by VAM2-6 compound by slowing down the parasite replication, retarding the patency time and increasing their survival time. It seems that VAM2-6 keep the development of the parasite under control but does not kill it, so the drug allows the infection to progress and probably allow the host immune system to generate a strong response leading to parasite clearance as reported previously with other compounds (Arora and Srivastava 2005; Moneriz et al. 2011) . Some drugs reported in the literature hinder the plasmodial infection progress by proteases and/or phosphatases inhibition or by inhibition of isoprenoid biosynthesis (Goulart et al. 2004; Höfle et al. 2008; Qiu et al. 2009; Quéré et al. 1996) .
Administration of substances directly into the mouth, by oral gavage, is probably one of the most common routes in laboratory animal medicine and research (Turner et al. 2011) . Limitations of oral dosage may include a slower onset of action compared with parenteral delivery, a potentially significant first-pass effect by the liver for those substances metabolized through this route with reduced efficacy, lack of absorption of substances due to chemical polarity, or interference with absorption by ingesta, lack of systemic absorption from the digestive tract, and degradation of substances by digestive enzymes and acid (Becker 2006 ). We do not know yet the pharmacodynamics and pharmacokinetics of VAM2-6, neither of the compound has a first-pass metabolism in the liver occurring after absorption when oral dosing is used, so maybe an incomplete absorption in the intestinal tract or the inactivation of some metabolites in the liver could be the reason for the low cured animal percentage obtained in this study.
In conclusion, chloroquine-treated group cured 100 % of mice at a dose of 5 mg/kg, VAM2-6 only cured the 20 % of the animals at 20 mg/kg but retarded the parasitemia and increases the survival time. To obtain the highest rate of cured animals, the compound dose would have to be elevated but it will become toxic to the host. Although compound VAM2-6 was active at higher doses than chloroquine and at lower doses than other quinoxline derivatives reported previously (Rangisetty et al. 2001) , these results leaves an open door to the study of its structure, pharmacokinetics, and mode of action in order to improve its antimalarial activity.
